Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Johnson and Johnson
Farmers Insurance
Mallinckrodt
Merck
Argus Health
Moodys
AstraZeneca

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,270,800

« Back to Dashboard

Which drugs does patent 7,270,800 protect, and when does it expire?

Patent 7,270,800 protects VIZAMYL and is included in one NDA.

This patent has forty-seven patent family members in eighteen countries.
Summary for Patent: 7,270,800
Title:Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
Inventor(s): Klunk; William E. (Pittsburgh, PA), Mathis, Jr.; Chester A. (Pittsburgh, PA), Wang; Yanming (Imperial, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Application Number:10/388,173
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,270,800

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y DIAGNOSTIC RADIOIMAGING ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y DIAGNOSTIC RADIOIMAGING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,270,800

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,833,458 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
9,134,328 Methods of using benzothiazole derivative compounds and compositions ➤ Sign Up
8,236,282 Benzothiazole derivative compounds, compositions and uses ➤ Sign Up
8,404,213 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
Argus Health
Julphar
Accenture
Johnson and Johnson
Boehringer Ingelheim
Fuji
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.